# Pizarra — PT-pseudo_075dd468b384 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_075dd468b384
Task: 1

Encounter: Urology - outpatient on 12 Jan 2025.
Referrer: Dr. L. Smits (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 66-year-old male
  - PSA: 13.2 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.14 ng/mL²
  - PSA velocity: 2.7 ng/mL/yr
  - Prior PSA: 10.2 ng/mL
  - Prostate volume: 96.0 mL
  - Months since last PSA: 3
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.6351894 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Hypercholesterolaemia
  - Problem list / PMHx: Hypertension, Hypercholesterolaemia
  - Current medication: amlodipine, atorvastatin, simvastatin
  - Allergies: NSAIDs
  - Additional notes: PSA 13.2 ng/mL. PI-RADS 4. PSAD 0.14. Prostate volume 96 mL. DRE nodus. csPCa 0.64.

Vitals: weight 60 kg, height 178 cm, BMI 18.9, BP 146/82 mmHg, HR 70 bpm. Smoking: Ex-smoker (33 pack-yr, quit 2010).

Chief complaint: Specialist reassessment sought due to a steadily rising PSA curve alongside historical biopsy results.

History: A 66-year-old office administrator arrives for specialist review after an initial PSA elevation in 2022. Married and settled in an independent unit of a retirement community, he walks 45 minutes daily and avoids alcohol entirely. His medical background encompasses hypertension and hypercholesterolaemia, treated with amlodipine, atorvastatin, and simvastatin. A substantial smoking history of 33 pack-years was concluded in 2010. Lower urinary tract complaints remain mild, scoring 5 out of 35 on the IPSS. Documented hypersensitivity to NSAIDs exists, necessitating large-print correspondence, and his brother serves as his designated next of kin. Unrelated to the current urological focus, he had uncomplicated cataract extraction in 2018, recently visited a sleep clinic for suspected obstructive sleep apnoea, and maintains routine podiatry appointments for foot care.

Physical examination: DRE — texture: firm; asymmetry: present; location: left posterior peripheral zone (Nodus). The remainder of the abdominal and cardiovascular assessment proves unremarkable, recording a blood pressure of 146/82 mmHg and a heart rate of 70 bpm. General inspection reveals a slender physique with a BMI of 18.9, alongside adequate nutritional status and an absence of acute distress.

Patient info: office administrator; Married; Lives in retirement community (independent unit).
Next of kin: Sibling (brother).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Walking 45 min/day; IPSS score: 5/35 (mild LUTS).

Recent other appointments: Cardiology — annual review (stable, autumn 2024); Sleep clinic — suspected obstructive sleep apnoea; Podiatry — routine foot care.
Admin: Visual impairment: large-print correspondence requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.41 +/- 0.20   (95% CI 0.07-0.82)

Where the uncertainty comes from:
  - aleatoric  dA = 0.17  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.11  (few labelled cases resemble this one)
  - 4.9 effective neighbours out of 10; 2 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=4.0, bx_ord=3.0, psa=13.2, age=66.0, psad=0.14, dre_ord=1.0, vol=96.0, n_pmhx=2.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only considered the visible panel data (PI-RADS=4, PSA=13.2, prior positive biopsy) and failed to weigh the clinical context, such as the rising PSA velocity (2.7 ng/mL/yr), the specific PSA density (0.14 ng/mL²), and the fact that the prior biopsy was positive, which fundamentally changes the question from "does he have cancer" to "is the existing cancer progressing or is there a new lesion."

WHY THE SUGGESTION COULD BE WRONG
The prior suggested NO BIOPSY with a wide uncertainty interval (0.41 +/- 0.20). This wide interval suggests the classifier is genuinely unable to distinguish between biopsy and no biopsy based on the limited input. Specifically, the prior fails to account for the clinical dilemma: a high PI-RADS score (4) combined with a rising PSA and a prior positive biopsy creates a situation where deferral might miss progression, or biopsy might be indicated for confirmation of the existing disease.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - does the lesion compare with a previous MRI?
PSA history - trend / velocity beyond the headline value
laboratory panel - full panel
previous GP / urology notes - to ascertain the specific nature of the prior positive biopsy
family-history of prostate cancer anamnesis

GUIDELINE ANCHOR
The guideline search indicates that the decision depends on whether the prior biopsy was systematic or targeted, whether the MRI is stable, and the specific PSA density relative to risk categories (Table 5.5).

## [5] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
{"case_id": "PT-pseudo_075dd468b384", "radiology_report": "Amsterdam UMC \u2013 Radiology Division\nDate: 10 Jan 2025 | Modality: Multiparametric MRI Prostate\n\nClinical context: Risk reassessment following a PSA reading of 13.2 ng/mL and a previously positive biopsy. Initial screening flagged a potential PI-RADS 4 focus.\n\nImaging Details: The gland demonstrates marked hypertrophy, totaling 96.0 mL in overall volume. Within the left mid-gland peripheral zone, a 12 x 8 mm focus exhibits restricted diffusion on DWI/ADC alongside early enhancement on DCE sequences. T2-weighted sequences reveal intermediate signal intensity; capsular integrity remains intact with no seminal vesicle involvement. Benign nodular hyperplasia diffusely expands the transition zone.\n\nImpression:\nPI-RADS 4 lesion in the left mid-gland peripheral zone.\nProstate volume 96.0 mL yielding a PSA density of 0.14 ng/mL/mL.\ncsPCa predicted probability 0.6351894."}
get_psa_trend
{"case_id": "PT-pseudo_075dd468b384", "psa_trend": [{"date": "Aug 2022", "val": 1.6}, {"date": "Jun 2023", "val": 3.2}, {"date": "Mar 2024", "val": 6.5}, {"date": "Jan 2025", "val": 13.2}]}
get_previous_notes
{"case_id": "PT-pseudo_075dd468b384", "previous_notes": [{"date": "17 May 2024", "author": "Dr. L. Smits (GP)", "text": "17 May 2024 \u2013 Dr. L. Smits (GP): A routine follow-up encounter took place. Laboratory data from March 2024 indicate a PSA level of 10.2 ng/mL, reflecting a steady climb from the first elevation noted in 2022. The patient continues amlodipine and statin therapy to manage hypertension and hypercholesterolaemia, demonstrating consistent compliance. Relevant laboratory and imaging documentation was transmitted to the urology department."}, {"date": "14 Sep 2024", "author": "Dr. L. Smits (GP)", "text": "14 Sep 2024 \u2013 Dr. L. Smits (GP): A consultation addressed the continuing urological evaluation. Blood pressure remains stable under the current therapeutic regimen, and lipid parameters are steady following an autumn cardiology assessment. The individual reports only baseline mild urinary frequency without additional complaints. Overall health status shows no deviation."}]}
get_lab_results
{"case_id": "PT-pseudo_075dd468b384", "laboratory_results": [{"name": "PSA", "val": "13.2 ng/mL", "date": "18 Dec 2024", "flag": "H"}, {"name": "Free PSA", "val": "1.57 ng/mL", "date": "18 Dec 2024", "flag": ""}, {"name": "%Free PSA", "val": "12%", "date": "18 Dec 2024", "flag": "L"}, {"name": "Haemoglobin", "val": "15.6 g/dL", "date": "18 Dec 2024", "flag": ""}, {"name": "WBC", "val": "6.6 x10^9/L", "date": "18 Dec 2024", "flag": ""}, {"name": "Platelets", "val": "302 x10^9/L", "date": "18 Dec 2024", "flag": ""}, {"name": "Creatinine", "val": "87 umol/L", "date": "18 Dec 2024", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "18 Dec 2024", "flag": ""}, {"name": "Testosterone", "val": "17.3 nmol/L", "date": "18 Dec 2024", "flag": ""}, {"name": "Alkaline phosphatase", "val": "83 U/L", "date": "18 Dec 2024", "flag": ""}, {"name": "LDH", "val": "147 U/L", "date": "18 Dec 2024", "flag": ""}, {"name": "HbA1c", "val": "6.6 %", "date": "18 Dec 2024", "flag": ""}]}

NOT RETRIEVED
The pathology report was not retrieved because the task description indicated it was not on file for this specific decision.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- MRI report: PI-RADS 4 lesion in the left mid-gland peripheral zone with restricted diffusion and early enhancement.
- PSA trend: Rising velocity of 2.7 ng/mL/yr, with PSA increasing from 10.2 ng/mL (Mar 2024) to 13.2 ng/mL (Jan 2025).
- Previous notes: The patient is undergoing re-evaluation due to a steadily rising PSA curve.

AGAINST sampling this patient now:
- Previous notes: The prior biopsy result is documented, meaning the diagnosis is established.
- Lab results: %Free PSA is 12%, which is not explicitly flagged as high risk in the retrieved data.

WHERE THIS LEANS
The evidence strongly suggests that the presence of a high-risk lesion identified on MRI (PI-RADS 4) combined with a rising PSA trajectory warrants further investigation, leaning towards a recommendation for biopsy to characterize the existing disease.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [6] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [7] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: borderline)

Although the patient has a prior positive biopsy, the combination of a high PI-RADS 4 lesion identified on MRI and a significant PSA velocity of 2.7 ng/mL/yr warrants further investigation to characterize the existing disease. The PSA level of 13.2 ng/mL is also a key factor driving the need for clarification. Since the retrieved documents do not document a prior ISUP grade, sampling is indicated to determine if the existing cancer is progressing or if the new MRI finding represents a distinct entity.

Variables that carried weight: bx=important, age=important, dre=noted, psa=decisive, vol=noted, psad=important, pirads=important, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
